blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1027894

EP1027894 - Pharmaceutical preparation for the treatment of inflammatory processes [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  20.06.2008
Database last updated on 19.07.2024
Most recent event   Tooltip20.06.2008Refusal of applicationpublished on 23.07.2008  [2008/30]
Applicant(s)For all designated states
CSL Behring GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
[2007/12]
Former [2004/35]For all designated states
ZLB Behring GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
Former [2000/33]For all designated states
Aventis Behring Gesellschaft mit beschränkter Haftung
Postfach 1230
35002 Marburg / DE
Inventor(s)01 / Römisch, Jürgen, Dr.
Zum Eisenberg 8
35041 Marburg / DE
02 / Dickneite, Gerhard, Dr.
Zum Neuen Hieb 31
35043 Marburg / DE
03 / Gronski, Peter, Dr.
Kirchgraben 5
35041 Marburg / DE
04 / Vohwinkel, Bernhard, Dr.
Lahnblick 3
35041 Marburg / DE
05 / Stauss, Harald
Pitzacker 6
35232 Dautphetal / DE
06 / Gray, Elaine, PhD
112 Westcott Crescent
Hanwell, London W7 1PB / GB
07 / Souter, Pauline J.
21 Latium Close, Holywell Hill
St. Albans, Hertfordshire AL1 1XU / GB
08 / Poole, Stephen, PhD
72 Grasmere Ave.
London SW19 3DX / GB
[2000/33]
Application number, filing date00101143.621.01.2000
[2000/33]
Priority number, dateEP1999010180828.01.1999         Original published format: EP 99101808
[2000/33]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1027894
Date:16.08.2000
Language:EN
[2000/33]
Type: A3 Search report 
No.:EP1027894
Date:24.01.2001
[2001/04]
Search report(s)(Supplementary) European search report - dispatched on:EP08.12.2000
ClassificationIPC:A61K38/55
[2001/03]
CPC:
A61K38/57 (EP); A61P19/00 (EP); A61P29/00 (EP);
A61P37/00 (EP)
Former IPC [2000/33]A61K38/55, A61P19/00, A61P29/00, A61P37/00
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2000/33]
TitleGerman:Pharmazeutische Zubereitungen zur Behandlung von entzündlichen Prozessen[2000/33]
English:Pharmaceutical preparation for the treatment of inflammatory processes[2000/33]
French:Préparation pharmaceutique pour le traitement des processus inflammatoires[2000/33]
Examination procedure24.07.2001Examination requested  [2001/38]
31.03.2003Despatch of a communication from the examining division (Time limit: M06)
18.11.2003Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
14.01.2004Reply to a communication from the examining division
07.09.2005Cancellation of oral proceeding that was planned for 16.09.2005
07.09.2005Minutes of oral proceedings despatched
16.09.2005Date of oral proceedings (cancelled)
05.03.2008Despatch of communication that the application is refused, reason: substantive examination [2008/30]
15.03.2008Application refused, date of legal effect [2008/30]
Request for further processing for:14.01.2004Request for further processing filed
14.01.2004Full payment received (date of receipt of payment)
Request granted
06.02.2004Decision despatched
Fees paidRenewal fee
31.01.2002Renewal fee patent year 03
31.01.2003Renewal fee patent year 04
02.02.2004Renewal fee patent year 05
31.01.2005Renewal fee patent year 06
31.01.2006Renewal fee patent year 07
31.01.2007Renewal fee patent year 08
31.01.2008Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]EP0629406  (BEHRINGWERKE AG [DE]) [A] * the whole document *
 [A]  - JONES H W ET AL, "Inactivation of antithrombin III in synovial fluid from patients with rheumatoid arthritis.", ANNALS OF THE RHEUMATIC DISEASES, (199803), vol. 57, no. 3, ISSN 0003-4967, pages 162 - 165, XP000961081 [A] 1-4 * the whole document *
 [A]  - GABAZZA ESTEBAN CESAR ET AL, "Correlation between clotting and collagen metabolism markers in rheumatoid arthritis.", THROMBOSIS AND HAEMOSTASIS, (1994), vol. 71, no. 2, ISSN 0340-6245, pages 199 - 202, XP000961108 [A] 1-4 * the whole document *
 [A]  - OZORAN K ET AL, "Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's disease.", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (1995), Database accession no. PREV199698680301, XP002153787 [A] 1-4 * abstract *
    [ ] - SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, (1995), vol. 24, no. 6, ISSN 0300-9742, pages 376 - 382
 [A]  - OKAJIMA K ET AL, "The anti-inflammatory properties of antithrombin III: new therapeutic implications.", SEMINARS IN THROMBOSIS AND HEMOSTASIS, (1998) 24 (1) 27-32, XP002116841 [A] 1-4 * the whole document *
 [A]  - DICKNEITE, G. (1), "Preclinical evaluation of antithrombin III in experimental sepsis and DIC.", BLOOD, (NOV. 15, 1998) VOL. 92, NO. 10 SUPPL. 1 PART 1-2, PP. 357A. MEETING INFO.: 40TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY MIAMI BEACH, FLORIDA, USA DECEMBER 4-8, 1998 THE AMERICAN SOCIETY OF HEAMATOLOGY., XP002116842 [A] * the whole document *
 [A]  - NIELSEN J.D. ET AL, "The effect of antithrombin on the systemic inflammatory response in disseminated intravascular coagulation.", BLOOD COAGULATION AND FIBRINOLYSIS, (1998) 9/SUPPL. 3 (S11-S15)., XP002116843 [A] * the whole document *
 [A]  - RISBERG B. ET AL, "Antithrombin: Facts and new hypotheses.", BLOOD COAGULATION AND FIBRINOLYSIS, (1998) 9/SUPPL. 3 (S3-S6)., XP002116844 [A] * the whole document *
 [A]  - OKAJIMA, K., "New therapeutic implications of antithrombin III replacement in disseminated intravascular coagulation and multiple organ failure.", INTENSIVMEDIZIN UND NOTFALLMEDIZIN, (1996) VOL. 33, NO. 1, PP. 5-11., XP002116845 [A] * the whole document *
 [A]  - MAMMEN, EBERHARD F., "Antithrombin: its physiological importance and role in DIC", SEMIN. THROMB. HEMOSTASIS (1998), 24(1), 19-25, XP002116846 [A] * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.